Relay Therapeutics, Inc.
RLAY
$2.83
-$0.285-9.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.68M | 10.01M | 10.01M | 35.21M | 35.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.68M | 10.01M | 10.01M | 35.21M | 35.33M |
| Cost of Revenue | 306.85M | 315.44M | 324.88M | 329.75M | 325.96M |
| Gross Profit | -299.17M | -305.43M | -314.87M | -294.55M | -290.64M |
| SG&A Expenses | 79.18M | 80.24M | 80.09M | 78.82M | 78.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 386.03M | 395.68M | 404.96M | 408.57M | 404.76M |
| Operating Income | -378.35M | -385.67M | -394.96M | -373.37M | -369.44M |
| Income Before Tax | -333.39M | -337.71M | -345.20M | -322.83M | -329.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -333.39 | -337.71 | -345.20 | -322.83 | -329.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -333.39M | -337.71M | -345.20M | -322.83M | -329.12M |
| EBIT | -378.35M | -385.67M | -394.96M | -373.37M | -369.44M |
| EBITDA | -373.07M | -380.21M | -389.45M | -367.87M | -363.97M |
| EPS Basic | -2.23 | -2.40 | -2.61 | -2.52 | -2.64 |
| Normalized Basic EPS | -1.45 | -1.56 | -1.71 | -1.66 | -1.69 |
| EPS Diluted | -2.23 | -2.40 | -2.61 | -2.52 | -2.64 |
| Normalized Diluted EPS | -1.45 | -1.56 | -1.71 | -1.66 | -1.69 |
| Average Basic Shares Outstanding | 609.62M | 571.23M | 528.65M | 510.65M | 499.51M |
| Average Diluted Shares Outstanding | 609.62M | 571.23M | 528.65M | 510.65M | 499.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |